Immunocryosurgery for Treatment of Locally Advanced BCC: A Case Report
Main Article Content
Abstract
BCC is the most common skin cancer (75%) in humans and the most common malignant tumor in the Caucasian population. The literature recognizes that 95% of BCCs are easy to treat surgically; however, when surgery is contraindicated due to patient or lesion-related conditions pharmacological and destructive therapies are reasonable alternatives. New therapeutic modalities, such as combined therapy, have been proven successful in the treatment of locally advanced and difficult-to-treat BCCs.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Peris K, Fargnoli MC, Garbe C, Kaufmann R, Bastholt L, Seguin NB, et al. Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines. Eur J Cancer. 2019 Sep;118:10–34.
II. Habashy S, Jafri A, Osman HO, Thomas NE, Udekwe S, Heindl SE. Hedgehog Pathway Inhibitors: Clinical Implications and Resistance in the Treatment of Basal Cell Carcinoma. Cureus. 2021 Mar 12;13(3):e13859.
III. Castillo Molina DA, Fierro Lozada JD, García C AM, Molano Pérez MA, Avilez MC, Guerrero-Roncancio L, et al. 27143 Cryotherapy as an adjuvant in the treatment with vismodegib for local advanced nonsurgical basal cell carcinoma: A report of 8 cases. J Am Acad Dermatol. 2021 Sep;85(3):AB131.
IV. Parriego SF. Crioterapia como terapia coadyuvante al vismodegib en carcinoma basocelular localmente avanzado [Internet]. [cited 2024 May 17]. Available from: https://dermatologiarevistamexicana.org.mx/article/crioterapia-como-terapia-coadyuvante-al-vismodegib-en-carcinoma-basocelular-localmente-avanzado/
V. Messeguer F, Serra-Guillen C, Echeverria B, Requena C, Sanmartin O, Llombart B, et al. A pilot study of clinical efficacy of imiquimod and cryotherapy for the treatment of basal cell carcinoma with incomplete response to imiquimod. J Eur Acad Dermatol Venereol. 2012 Jul;26(7):879–81